No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoIl CDC emette un avviso di livello 4 entro il 31 dicembre?
Sì
$71,851 Vol.
$71,851 Vol.
Sì
$71,851 Vol.
$71,851 Vol.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Mercato aperto: Jan 19, 2026, 3:15 PM ET
Resolver
0x65070BE91...A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti